

Table 19.31
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2009-2015

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	81,485	72.1 (71.7 , 72.5)	90.8 (89.8 , 91.8)	81.3 (80.8 , 81.8)	62.1 (61.4 , 62.8)				
1 Hodgkin Lymphoma	6,512	87.8 (86.8 , 88.8)	97.1 (95.6 , 98.1)	92.1 (91.1 , 92.9)	57.4 (52.9 , 61.6)				
2 Non-Hodgkin lymphoma	73,067	71.1 (70.6 , 71.5)	89.0 (87.7 , 90.2)	79.7 (79.1 , 80.2)	62.8 (62.1 , 63.5)				
2(a) Non-Hodgkin lymphoma, B-cell	68,302	71.3 (70.8 , 71.8)	89.7 (88.3 , 90.9)	80.1 (79.5 , 80.7)	63.3 (62.6 , 64.1)				
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,951	69.6 (67.9 , 71.2)	89.7 (88.2 , 91.0)	41.9 (38.3 , 45.4)	21.1 (15.9 , 26.7)				
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	60,381	71.6 (71.1 , 72.1)	89.4 (85.2 , 92.5)	81.7 (81.1 , 82.3)	63.8 (63.0 , 64.6)				
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	12,913	83.3 (82.2 , 84.4)	100.0 (- , -)	91.3 (90.0 , 92.4)	78.9 (77.3 , 80.5)				
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	11,666	85.4 (84.2 , 86.6)	100.0 (- , -)	93.4 (92.1 , 94.4)	81.0 (79.3 , 82.7)				
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	31	39.6 (17.8 , 60.9)	100.0 (- , -)	34.9 (1.3 , 77.4)	33.4 (10.8 , 58.3)				
2(a) 2.1.3. Mantle-cell lymphoma	1,216	64.2 (60.3 , 67.8)	- (- , -)	72.5 (67.0 , 77.3)	59.2 (53.8 , 64.2)				
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,286	85.5 (81.7 , 88.6)	100.0 (- , -)	90.8 (86.4 , 93.8)	82.4 (76.8 , 86.7)				
2(a) 2.2.1. Lymphoplasmacytic lymphoma	610	84.0 (78.4 , 88.3)	100.0 (- , -)	86.4 (79.6 , 91.0)	82.0 (73.4 , 88.0)				
2(a) 2.2.2. Waldenstrom macroglobulinemia	676	86.8 (81.1 , 90.8)	- (- , -)	94.9 (88.2 , 97.8)	82.6 (74.7 , 88.3)				
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,762	63.2 (62.2 , 64.1)	87.2 (80.7 , 91.6)	76.1 (74.9 , 77.3)	53.1 (51.6 , 54.5)				
2(a) 2.3.1. DLBCL, NOS ^c	15,450	62.8 (61.8 , 63.7)	86.8 (79.9 , 91.4)	75.6 (74.4 , 76.8)	53.1 (51.6 , 54.5)				
2(a) 2.3.2. Intravascular large B-cell lymphoma	42	57.5 (39.5 , 71.9)	- (- , -)	56.1 (30.1 , 75.8)	57.0 (32.3 , 75.6)				
2(a) 2.3.3. Primary effusion lymphoma	5	- (- , -)	- (- , -)	- (- , -)	0.0 (- , -)				
2(a) 2.3.4. Mediastinal large B-cell lymphoma	265	88.1 (82.8 , 91.8)	91.7 (53.8 , 98.8)	89.9 (84.5 , 93.5)	37.4 (9.5 , 66.3)				
2(a) 2.4. Burkitt lymphoma/leukemia	583	60.6 (56.0 , 64.9)	92.1 (84.2 , 96.2)	59.6 (53.3 , 65.3)	36.4 (28.2 , 44.7)				
2(a) 2.5. Marginal-zone lymphoma (MZL)	5,391	91.6 (90.1 , 92.9)	94.8 (68.0 , 99.2)	95.4 (93.9 , 96.5)	88.3 (85.6 , 90.5)				
2(a) 2.5.1. Splenic MZL	446	89.3 (83.9 , 93.0)	- (- , -)	93.0 (85.3 , 96.7)	86.3 (79.1 , 91.1)				
2(a) 2.5.2. Extranodal MZL, MALT ^c type	3,425	94.2 (92.4 , 95.6)	93.8 (63.2 , 99.1)	96.3 (94.6 , 97.5)	91.9 (88.4 , 94.4)				
2(a) 2.5.3. Nodal MZL	1,520	86.2 (83.0 , 88.8)	100.0 (- , -)	93.2 (89.7 , 95.6)	80.7 (75.6 , 84.8)				
2(a) 2.6. Follicular lymphoma	8,770	88.4 (87.3 , 89.5)	90.1 (46.9 , 98.6)	94.0 (92.9 , 94.9)	82.0 (79.8 , 83.9)				
2(a) 2.7. Hairy-cell leukemia	314	91.1 (84.8 , 94.9)	- (- , -)	97.5 (93.0 , 99.1)	76.4 (60.6 , 86.6)				
2(a) 2.8. Plasma cell neoplasms	15,354	52.3 (51.2 , 53.4)	75.6 (32.4 , 93.3)	65.7 (64.2 , 67.2)	43.0 (41.5 , 44.5)				
2(a) 2.8.1. Plasmacytoma	795	72.7 (68.1 , 76.6)	85.7 (33.4 , 97.9)	83.2 (77.7 , 87.5)	59.9 (52.7 , 66.3)				
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	14,559	51.2 (50.1 , 52.3)	0.0 (- , -)	64.4 (62.8 , 66.0)	42.2 (40.7 , 43.7)				
2(a) 2.9. Heavy chain disease	8	63.8 (22.7 , 87.3)	- (- , -)	- (- , -)	41.4 (5.1 , 77.0)				
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,970	69.2 (67.0 , 71.2)	87.7 (59.0 , 96.8)	82.6 (79.8 , 85.0)	62.6 (59.7 , 65.4)				

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2009-2015

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	4,550	67.4 (65.7 , 69.1)	85.4 (81.4 , 88.7)	75.1 (73.1 , 77.0)	51.5 (48.2 , 54.6)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	56	67.9 (53.7 , 78.7)	91.7 (70.6 , 97.9)	62.0 (39.2 , 78.3)	- (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	4,487	67.4 (65.7 , 69.1)	85.0 (80.8 , 88.4)	75.3 (73.2 , 77.2)	51.6 (48.3 , 54.8)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,213	92.8 (89.8 , 94.9)	100.0 (- , -)	96.0 (93.2 , 97.6)	86.0 (78.5 , 91.0)			
2(b) 2.1.1. Mycosis fungoides	1,171	94.5 (91.5 , 96.5)	100.0 (- , -)	97.4 (94.5 , 98.7)	88.3 (80.4 , 93.1)			
2(b) 2.1.2. Sezary syndrome	42	38.2 (20.7 , 55.5)	- (- , -)	39.6 (14.8 , 63.9)	35.5 (13.1 , 59.0)			
2(b) 2.2. Peripheral T-cell lymphoma	2,474	60.4 (58.0 , 62.7)	88.5 (80.3 , 93.4)	71.5 (68.5 , 74.2)	43.6 (39.6 , 47.5)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	851	39.5 (35.5 , 43.5)	56.6 (26.8 , 78.2)	51.9 (46.2 , 57.2)	27.7 (22.3 , 33.3)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	343	41.1 (34.6 , 47.5)	- (- , -)	60.4 (49.7 , 69.5)	30.1 (22.4 , 38.1)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	54	91.7 (75.0 , 97.4)	100.0 (- , -)	86.0 (63.9 , 95.0)	100.0 (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	430	72.8 (67.6 , 77.3)	91.0 (79.4 , 96.2)	77.7 (71.4 , 82.7)	46.3 (36.1 , 55.9)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	21	12.6 (1.0 , 39.2)	- (- , -)	12.7 (1.0 , 39.5)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	31	8.6 (1.6 , 23.5)	- (- , -)	0.0 (- , -)	13.5 (2.3 , 34.3)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	512	84.6 (79.4 , 88.5)	100.0 (- , -)	89.4 (83.9 , 93.1)	74.9 (64.2 , 82.9)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	232	89.5 (81.2 , 94.3)	92.3 (56.6 , 98.9)	93.2 (85.6 , 96.8)	82.0 (60.8 , 92.4)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	525	59.6 (54.5 , 64.3)	81.7 (75.7 , 86.4)	47.7 (39.4 , 55.6)	23.5 (12.8 , 36.1)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	182	42.6 (34.3 , 50.6)	- (- , -)	47.6 (38.0 , 56.5)	29.8 (14.9 , 46.2)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	16	66.3 (30.8 , 86.7)	- (- , -)	85.8 (33.1 , 97.9)	44.9 (7.9 , 77.7)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	77	11.1 (4.1 , 21.8)	- (- , -)	23.8 (8.9 , 42.7)	0.0 (- , -)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	7	57.4 (17.1 , 84.0)	- (- , -)	50.1 (11.1 , 80.5)	100.0 (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	215	57.6 (49.6 , 64.8)	90.2 (72.3 , 96.7)	56.7 (44.1 , 67.5)	46.9 (35.3 , 57.7)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	69	70.5 (57.3 , 80.2)	90.2 (72.3 , 96.7)	56.5 (34.6 , 73.6)	34.1 (7.9 , 63.5)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	9	22.8 (3.4 , 52.4)	- (- , -)	- (- , -)	22.8 (3.4 , 52.4)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	137	53.1 (42.7 , 62.5)	- (- , -)	56.8 (41.1 , 69.8)	50.1 (36.9 , 61.9)			
2(*) 1. Total precursor lymphoma/leukemia ^d	4,076	69.6 (68.0 , 71.2)	89.7 (88.2 , 91.0)	42.9 (39.5 , 46.3)	21.5 (16.5 , 27.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	127	69.6 (57.1 , 79.1)	- (- , -)	83.2 (68.5 , 91.5)	52.4 (31.4 , 69.7)			
4 Lymphoid neoplasm, NOS ^c	1,779	54.2 (51.3 , 57.1)	86.3 (70.8 , 93.9)	75.8 (71.7 , 79.3)	41.2 (37.3 , 45.1)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.